Please assess the completion status of the following clinical trial:

Trial Title: Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Polycystic Ovary Syndrome according to Rotterdam criteria,~* BMI ≥ 27 Kg/m2~Exclusion Criteria:~* Type 2 diabetes mellitus,~* in treatment for polycystic ovary syndrome features

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin 850mg twice a day for six months
- Magnesium (Type: EXPERIMENTAL): Magnesium chloride 250mg daily for six months
- PUFA omega 3 (Type: EXPERIMENTAL): Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months

Based on this trial design, predict the completion outcome and termination type (if applicable).